Alagöz Holding

Alagöz Holding is a prominent Turkish conglomerate with a significant presence in the healthcare and pharmaceutical sectors, primarily through its subsidiary Keymen İlaç. The company gained international recognition for its role in the distribution and Phase 3 clinical trials of the Sinovac COVID-19 vaccine in Turkey. In 2023, Alagöz Holding launched KeyVac, a joint venture with Sinovac Biotech, establishing a state-of-the-art vaccine manufacturing plant in Ankara to produce vaccines such as Hepatitis A locally. Beyond healthcare, the holding operates in energy, mining, aviation, and laboratory equipment, positioning itself as a key player in Turkey's industrial and scientific landscape.